The interaction between the immune system and cancer was an area of research interest for several decades.
The recent U.S. Food and Drug Administration approval of sipuleucel-T and ipilimumab stimulated broader interest in manipulating immunity to fight cancer. In the context of prostate cancer, the immunotherapy strategies under development are therapeutic vaccination strategies, such as sipuleucel-T and PROSTVAC-VF, or immune checkpoint blockade of CTLA-4. Improved understanding of the immune responses generated by the development of predictive biomarkers for patient selection will guide rational combinations of these treatments and provide new treatment options in prostate cancer.
Written by:
Pracht M, Herrera F, Tawadros T, Berthold D. Are you the author?
Département d'oncologie médicale, CHUV, 1011 Lausanne.
Reference: Rev Med Suisse. 2013 May 22;9(387):1070-5.
PubMed Abstract
PMID: 23757912
Article in French.
